2015 American Transplant Congress
Upregulation of Heart Transplant IL-33 Is Critical in Cardiac Tissue Repair
Starzl Transplantation Institute, Department of Surgery, Univ of Pittsburgh, Pittsburgh, PA.
Background: IL-33 is tissue-derived cytokine whose primary proposed function is to modulate immune responses when released during injury. Delivery of recombinant IL-33 protects cardiac allografts…2015 American Transplant Congress
Treatment of Subclinical Rejection Identified On Surveillance Biopsy May Prevent the Development of Chronic Alloimmune Injury
Imperial College Kidney and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
Surveillance biopsies [SBx] are not universally performed following renal transplantation. In patients in whom protocol biopsies are performed, how best to manage subclinical rejection [SCR]…2015 American Transplant Congress
Bortezomib Treatment in Antibody Mediated Rejection After Kidney Transplantation
BackgroundSeveral studies demonstrated bortezomib therapy for antibody-mediated rejection (AMR) in renal transplants. However, the treatment efficacy according to target antigen or occurrence time of AMR…2015 American Transplant Congress
Incidence and Impact of De Novo Donor-Specific Anti-HLA Antibodies in ABO-Compatible Liver-Transplant Recipients
Background: The incidence and consequences of de novo donor-specific anti-HLA antibodies (DSAs) after liver transplantation (LT) are not well known. Thus, we investigated the incidence,…2015 American Transplant Congress
Gene Expression Monitoring in Pediatric Heart Transplant Recipients
Allomap® gene expression testing is a non-invasive screening tool approved for use in heart transplant recipients age 15 and older. Experience with Allomap® in pediatric…2015 American Transplant Congress
Clinical Significance of Estimated DSA MFI Values at 1,000 C1q MFI for Differentiation Between Harmful and Harmless DSA
INTRODUCTIONControl of chronic antibody mediated rejection (CAMR) is essential for further improvement of long-term graft survival. Early detection of de novo donor specific antibodies (DSA)…2015 American Transplant Congress
Belatacept in a Community Hospital Adult Kidney Transplant Program
Iowa Methodist Medical Center, Des Moines, IA.
PURPOSE:This is a retrospective look (08/2011-11/2014) on data collected from patients transplanted at Iowa Methodist Transplant Center.METHODS:All patients were EBV positive. They were induced with…2015 American Transplant Congress
Biomarker Panel Profile for Identification of High-Risk Patients After Heart Transplantation
Background: The first year after cardiac transplantation is critical for transplant survival and long-term outcome. Identification of suitable biomarkers for detection of rejection processes is…2015 American Transplant Congress
Increasing Tacrolimus Exposure to Minumize Chronic Rejection: How Can We Do It? What Are the Risks?
Background: Recent studies suggest that increased tacrolimus (TAC) exposure may help prevent production of donor specific HLA antibodies (DSAs) that mediate chronic rejection of renal…2015 American Transplant Congress
Risk Factors for Acute Cellular Rejection for Pediatric Kidney Transplant Recipients
Background: Acute cellular rejection (ACR) potentially shortens the life of a kidney allograft. We sought to determine risk factors associated with the development of ACR…
- « Previous Page
- 1
- …
- 151
- 152
- 153
- 154
- 155
- …
- 172
- Next Page »